Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Implant or insert
Reexamination Certificate
2007-11-27
2007-11-27
Pryor, Alton (Department: 1616)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Implant or insert
C424S466000
Reexamination Certificate
active
09856417
ABSTRACT:
There is provided a method for preparing a tablet for the vaginal administration of progesterone for systemic use, comprising the steps of: slowly mixing water with micronized progesterone, the total amount of water mixed with said micronized progesterone not exceeding the maximum wetting capacity of the micronized progesterone, whereby to obtain wetted micronized progesterone; drying said wetted, micronized progesterone to a humidity content of substantially 0%, whereby to form substantially dry micronized progesterone; mixing said substantially dry micronized progesterone with other pharmaceutically acceptable excipients or diluents therefor; and forming a tablet by direct compaction of said substantially dry micronized progesterone which has been mixed with said other pharmaceutically acceptable excipients or diluents therefor. Tablets so prepared, as well as a tablet comprising between about 6 to 20 wt. % progesterone and between about 5 to 12 wt. % effervescent, are also provided.
REFERENCES:
patent: 3121663 (1964-02-01), Parker
patent: 4310510 (1982-01-01), Sherman et al.
patent: 4853211 (1989-08-01), Kurobe et al.
patent: 5084277 (1992-01-01), Greco et al.
patent: 5116619 (1992-05-01), Greco et al.
patent: 5543150 (1996-08-01), Bologna et al.
patent: 5958455 (1999-09-01), Roser et al.
patent: 5993856 (1999-11-01), Ragavan et al.
patent: 6086916 (2000-07-01), Agnus et al.
Chakmakjian et al, Bioavailability of progesterone with different modes of administration, J. of Reprod. Med., 1987, 3(6), 443-8.
Bulletti, C. et al., Targeted drug delivery in gynaecology: the first uterine pass effect, Human Reproduction, 1997, vol. 12, pp. 1073-1079.
Ficiciouglu, C. et al., High local endometrial effect of vaginal progesterone gel, Gynecol Endocrinol., 2004, vol. 18, pp. 240-243.
Levy, T. et al., Pharmacokinetics of natural progesterone administered in the form of a vaginal tablet, Human Reproduction, 1999, vol. 14, pp. 606-610.
Levy, T. et al., Pharmacokinetics of the progesterone-containing vaginal tablet and its use in assisted reproduction, Steroids, 2000, vol. 65, pp. 645-649.
Lewin, A. et al., Simplified artificial endometrial preparation, using oral estradiol and novel vaginal progesterone tablets: a prospective randomized study, Gynecol Endocrinol, 2002, vol. 15, pp. 131-136.
Maymon, R. and Schulman, A., Comparison of triple serum screening and pregnancy outcome in oocyte donation versus IVF pregnancies, Human Reproduction, 2001, vol. 16, pp. 691-695.
Schulman, A. et al., The best donor, Human Reproduction, 1999, vol. 14, pp. 2493-2496.
Darby & Darby
Ferring B.V.
Pryor Alton
LandOfFree
Vaginally administrable progesterone-containing tablets and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Vaginally administrable progesterone-containing tablets and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Vaginally administrable progesterone-containing tablets and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3832239